DoD spent $253M on nasal swabs, a significant investment in the COVID-19 industrial base expansion

Contract Overview

Contract Amount: $252,889,594 ($252.9M)

Contractor: Puritan Medical Products Company I LP

Awarding Agency: Department of Defense

Start Date: 2021-01-08

End Date: 2022-01-08

Contract Duration: 365 days

Daily Burn Rate: $692.8K/day

Competition Type: NOT COMPETED

Number of Offers Received: 1

Pricing Type: FIRM FIXED PRICE

Sector: Healthcare

Official Description: COVID-19 INDUSTRIAL BASE EXPANSION OF FOAM TIP NASAL SWABS

Place of Performance

Location: GUILFORD, PISCATAQUIS County, MAINE, 04443

State: Maine Government Spending

Plain-Language Summary

Department of Defense obligated $252.9 million to PURITAN MEDICAL PRODUCTS COMPANY I LP for work described as: COVID-19 INDUSTRIAL BASE EXPANSION OF FOAM TIP NASAL SWABS Key points: 1. The contract value represents a substantial commitment to securing a critical medical supply during a national emergency. 2. The sole-source nature of this award warrants scrutiny regarding potential price inflation and limited market engagement. 3. Performance duration of one year suggests a focused effort to meet immediate supply chain needs. 4. The firm-fixed-price structure offers cost certainty for the government, shifting risk to the contractor. 5. This award highlights the government's reliance on established manufacturers for essential goods in crisis situations. 6. The geographic concentration in Maine for manufacturing may have implications for broader supply chain resilience.

Value Assessment

Rating: fair

Benchmarking the value of $253 million for nasal swabs is challenging without specific volume data and comparable contracts from the same period. However, given the emergency nature of the COVID-19 pandemic, prices may have been elevated due to urgent demand and supply chain disruptions. The firm-fixed-price contract provides cost predictability, but the lack of competition raises concerns about whether the government secured the best possible value. Further analysis would require comparing unit costs to pre-pandemic benchmarks or other government awards for similar items.

Cost Per Unit: N/A

Competition Analysis

Competition Level: sole-source

This contract was awarded on a sole-source basis, meaning Puritan Medical Products Company I LP was the only vendor considered. This approach is typically used when only one responsible source can satisfy the agency's needs, often due to proprietary technology, urgent and compelling circumstances, or lack of market research. The absence of competition means there was no opportunity for other manufacturers to bid, potentially leading to higher prices than if multiple bids were received. This limits the government's ability to leverage market forces for cost savings.

Taxpayer Impact: The sole-source award means taxpayers did not benefit from competitive pricing, potentially resulting in a higher overall expenditure for these essential supplies.

Public Impact

The primary beneficiaries are healthcare providers and the general public, who received access to essential COVID-19 testing supplies. The contract ensured the supply of foam tip nasal swabs, a critical component for diagnostic testing. Manufacturing was concentrated in Maine, supporting local employment and the regional economy. This award contributed to the broader national effort to expand the industrial base for critical medical equipment during the pandemic.

Waste & Efficiency Indicators

Waste Risk Score: 50 / 10

Warning Flags

Sole-source award limits price discovery and potentially inflates costs for taxpayers.
Lack of competition raises questions about whether alternative, potentially more cost-effective, solutions were overlooked.
Geographic concentration of manufacturing could pose risks if disruptions occur in that specific region.

Positive Signals

Firm-fixed-price contract provides budget certainty for the government.
Award addresses a critical need for medical supplies during a national health crisis.
Supports domestic manufacturing and supply chain resilience for essential goods.

Sector Analysis

The healthcare manufacturing sector, specifically the production of medical supplies and devices, is a critical component of the national economy and public health infrastructure. This contract falls under the Surgical Appliance and Supplies Manufacturing industry (NAICS 339113). The COVID-19 pandemic placed immense pressure on this sector, leading to significant government investment to scale production and ensure availability of essential items like nasal swabs. Comparable spending benchmarks are difficult to establish due to the unique market conditions and urgent demand during the pandemic, but this award represents a substantial portion of government spending on this specific item.

Small Business Impact

This contract was not awarded as a small business set-aside, nor does it appear to have specific subcontracting requirements for small businesses mentioned in the provided data. The award to Puritan Medical Products Company I LP, a single large entity, suggests that the focus was on rapid scaling of production capacity to meet urgent demand. This approach may limit opportunities for small businesses to participate directly in this specific large-scale government contract, although they might be suppliers to the prime contractor.

Oversight & Accountability

Oversight for this contract would typically fall under the Department of Defense's contracting and financial management regulations. The firm-fixed-price nature provides a degree of financial oversight by locking in costs. Transparency regarding the justification for the sole-source award and the pricing structure would be key areas for scrutiny. Inspector General involvement could be triggered if any allegations of fraud, waste, or abuse arise during the contract's performance or close-out.

Related Government Programs

COVID-19 Testing Supplies Procurement
Medical Industrial Base Expansion
Department of Defense Supply Chain Management
Surgical Appliance and Supplies Manufacturing Contracts

Risk Flags

Sole-source award may lead to higher costs.
Lack of competition limits price discovery.
Urgent need justification requires careful review.
Concentration of manufacturing in one location poses supply chain risk.

Frequently Asked Questions

What is this federal contract paying for?

Department of Defense awarded $252.9 million to PURITAN MEDICAL PRODUCTS COMPANY I LP. COVID-19 INDUSTRIAL BASE EXPANSION OF FOAM TIP NASAL SWABS

Who is the contractor on this award?

The obligated recipient is PURITAN MEDICAL PRODUCTS COMPANY I LP.

Which agency awarded this contract?

Awarding agency: Department of Defense (Department of the Air Force).

What is the total obligated amount?

The obligated amount is $252.9 million.

What is the period of performance?

Start: 2021-01-08. End: 2022-01-08.

What was the specific justification for awarding this contract on a sole-source basis?

The provided data indicates the contract was 'NOT COMPETED,' which typically implies a sole-source award. The justification for sole-source procurement usually stems from 'urgent and compelling needs' where a delay in award would cause significant harm or loss to the government, or when only one responsible source is available. In the context of the COVID-19 pandemic, the rapid and unprecedented demand for medical supplies like nasal swabs likely created such urgent circumstances. The government may have determined that Puritan Medical Products Company I LP was the only entity capable of rapidly scaling production to meet the immediate national requirement, or that initiating a full and open competition would introduce unacceptable delays in securing critical supplies.

How does the contract value of $253 million compare to typical spending on nasal swabs before the pandemic?

Direct comparison of the $253 million contract value to pre-pandemic spending on nasal swabs is difficult without specific volume and unit cost data. However, it is highly probable that this figure represents a significant increase. The COVID-19 pandemic caused an unprecedented surge in demand for testing supplies, leading to market-wide price increases due to scarcity and expedited production needs. Pre-pandemic, nasal swabs were likely procured in much smaller quantities at lower unit costs. This award reflects the extraordinary circumstances of the pandemic, focusing on scaling domestic production capacity rather than routine procurement.

What are the potential risks associated with a sole-source award of this magnitude?

The primary risk of a sole-source award of this magnitude is the potential for inflated pricing due to the absence of competitive pressure. Without competing bids, the government may not achieve the most favorable price. Additionally, it limits the opportunity to explore innovative solutions or alternative suppliers that might offer better value or performance. There's also a risk that the government becomes overly reliant on a single supplier, creating vulnerabilities in the supply chain if that supplier faces production issues or other disruptions. Transparency in pricing negotiations and robust oversight become even more critical in sole-source situations.

What does the firm-fixed-price (FFP) contract type imply for cost control and risk allocation?

A firm-fixed-price (FFP) contract type means the price is set and not subject to adjustment based on the contractor's cost experience. This is generally favorable for the government as it provides cost certainty and shifts the risk of cost overruns entirely to the contractor. For Puritan Medical Products Company I LP, this means they must manage their production costs effectively to maintain profitability. The government knows the total expenditure upfront, simplifying budgeting and financial management. However, the FFP structure, combined with a sole-source award, means the government is locked into the negotiated price, regardless of whether the contractor achieves lower-than-expected costs.

What is the significance of this contract in the context of expanding the US industrial base for medical supplies?

This contract is highly significant as it directly addresses the critical need to expand the U.S. industrial base for essential medical supplies, particularly in response to the COVID-19 pandemic. The award of $253 million to Puritan Medical Products Company I LP signifies a substantial investment aimed at increasing the domestic production capacity of foam tip nasal swabs. This initiative is crucial for reducing reliance on foreign sources, ensuring national security, and building resilience against future public health emergencies. By bolstering domestic manufacturing capabilities, the government aims to create a more robust and responsive supply chain for critical healthcare products.

Are there any indications of contractor performance issues or successes in previous contracts with the government?

The provided data does not include information on Puritan Medical Products Company I LP's past performance on government contracts. A comprehensive assessment of this award would typically involve reviewing past performance evaluations, such as those found in the Contractor Performance Assessment Reporting System (CPARS). Without this information, it is difficult to assess the contractor's track record regarding quality, timeliness, cost control, and overall management. Given the sole-source nature and the critical need during the pandemic, the government likely prioritized the contractor's demonstrated ability to scale production rapidly, but a full risk assessment would necessitate examining their historical performance.

Industry Classification

NAICS: Manufacturing › Medical Equipment and Supplies Manufacturing › Surgical Appliance and Supplies Manufacturing

Product/Service Code: INSTALLATION OF EQUIPMENT › INSTALLATION OF EQUIPMENT

Competition & Pricing

Extent Competed: NOT COMPETED

Solicitation Procedures: ONLY ONE SOURCE

Offers Received: 1

Pricing Type: FIRM FIXED PRICE (J)

Evaluated Preference: NONE

Contractor Details

Address: 31 SCHOOL ST, GUILFORD, ME, 04443

Business Categories: Category Business, Corporate Entity Not Tax Exempt, Limited Liability Corporation, Manufacturer of Goods, Small Business, Special Designations, U.S.-Owned Business

Financial Breakdown

Contract Ceiling: $252,889,594

Exercised Options: $252,889,594

Current Obligation: $252,889,594

Contract Characteristics

Commercial Item: COMMERCIAL ITEM

Cost or Pricing Data: NO

Timeline